Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 246 participants.

Also called NCT04530617

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 246 participants (enrolled count) (from the registry)
Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (from the registry)
Registry
  • NCT NCT04530617
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04530617. Randomized; triple masking; primary purpose treatment. Start 2020-10-05 (actual); primary completion 2021-06-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients
Condition
Covid19
Condition
Diabetes
Condition
Hypertension
Condition
Obesity
Intervention (Drug)
Camostat Mesilate
Intervention (Drug)
Artemisia Annua Leaf
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (class: other)

Record details

Record id
cardio:ct-nct04530617
Content hash
cc12851c72def0ea83fed928eff683ac20f961dfab38b0dbc92ec135cd40f800